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Background: Anemia is a significant prognostic factor of mortality in Heart Failure (HF). Patients with refractory symptoms and end-organ 
hypoperfusion often require inotropes for clinical stabilization, however prognosis remains poor. We investigated the impact of anemia correction on 
the prognosis of inotrope-dependent HF patients.
Methods: We identified retrospectively 91 consecutive patients with decompensated HF, who required inotrope infusions, weekly or biweekly, for 3 
months. Anemia was defined as haemoglobin (Hb) <12gr/dl. Patients were divided into 3 groups: Group 1, 18 anemic patients who did not receive 
correction, Group 2,39 anemic patients who received anemia treatment and Group 3, 34 non anemic patients. The effect of anemia correction on 
patients’ survival was evaluated using Kaplan Meier curves.
Results: Baseline characteristics were similar between all groups. At 3 months, in Group 1, Hb remained unchanged (from 10.6 ±0.7 to 10.3±0.8 
gr/dl, p=0.09) while in Group 2 improved from 10.5± 0.8 to 11.9±1.8 gr/dl (p=0.003) and in Group 3 decreased, but not at the levels of Group 1 
(from 13.8 ±1.1 to 12.6±1.1 gr/dl, p<0.01). In Group 1 35.3% of patients were alive at 6 months in comparison to 60.5% in Group 2, and 61.8% in 
Group 3 (Figure 1).
Conclusions: In HF patients requiring inotropes for clinical stabilization, anemia was associated with worse outcome; anemia correction improved 
survival to the levels of non-anemic patients, with similar hemodynamic decompensation. 
 
